奧格列汀雜質(zhì) 奧格列汀異構(gòu)體對(duì)照品

時(shí)間：2017/4/12閱讀：1069

分享：

奧格列汀市場(chǎng)前景：奧格列汀為超長(zhǎng)效二肽基肽酶-4(DPP-4)抑制劑，其作用機(jī)制是通過(guò)抑制體內(nèi)DPP-4酶對(duì)胰高血糖素樣肽-1（GLP-1）的降解作用，延長(zhǎng)GLP-1的作用時(shí)間，從而提高血液中內(nèi)源性GLP-1和GIP的濃度，并zui終改善血糖控制。2013年抗糖尿病治療藥物銷(xiāo)售額達(dá)到了469億美元的市場(chǎng)規(guī)模，其中DPP-4抑制劑銷(xiāo)售市場(chǎng)達(dá)到93.88億美元，同比上一年增長(zhǎng)了10.24%，是快速發(fā)展的一類(lèi)藥物。

深圳遠(yuǎn)揚(yáng)化學(xué)可提供奧格列汀申報(bào)所用全套雜質(zhì)，隨貨附CoA證書(shū)，HNMR，MS，HPLC圖譜，純度符合申報(bào)要求，歡迎我司（何；phastandards；）。請(qǐng)點(diǎn)擊本頁(yè)標(biāo)題下方“進(jìn)入該公司展臺(tái)” 查看我司信息。

MK-3102	(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine
MK-3102 Impurity 1	tert-butyl ((2S,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate
MK-3102 Impurity 2	tert-butyl ((2S,3R)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate
MK-3102 Impurity 3	tert-butyl ((2R,3R)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate compound with tert-butyl ((2S,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate (1:1)
MK-3102 Impurity 4	tert-butyl ((2R,3S)-2-(2,3-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate
MK-3102 Impurity 5	tert-butyl ((2R,3S)-2-(3,4-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate
MK-3102 Impurity 6	1-(methylsulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole
MK-3102 Impurity 7	S,5R)-2-(2,5-difluorophenyl)-5-(1-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(1H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine
MK-3102 Impurity 8	(2R,3S,5S)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine
MK-3102 Impurity 9	(2S,3S,5S)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine
MK-3102 Impurity 10	(2S,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine
MK-3102 Impurity 11	(2S,3R,5S)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine
MK-3102 Impurity 12	(2R,3R,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine
MK-3102 Impurity 13	(2S,3R,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine
MK-3102 Impurity 14	(2R,3R,5S)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine
MK-3102 Impurity 15	(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine
MK-3102 Impurity 16	(R)-5-((3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-yl)-2-(methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole 5-oxide
MK-3102 Impurity 17	N-((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-yl)acetamide
MK-3102 Impurity 18	N-((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-yl)benzenesulfonamide